Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Incyte Corporation — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.36 (market cap $41.13B), while Incyte Corporation trades at $113.79 (market cap $22.85B). The key difference: iShares 7-10 Year Treasury Bond ETF is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | INCY | |
|---|---|---|
Market Cap | $41.13B | $22.85B |
Volume | 10,340,382 | 1,927,029 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $129.93 |
52-Week Low | $88.92 | $83.80 |
Typical Hold Time | — | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.335, up 0.25% with a bearish technical signal from moving averages. The fund shows neutral oscillator readings with RSI at 52.94. Recent dividend payments of $0.31-$0.33 provide income, while bond market volatility and rising Treasury yields create headwinds. Support is clustered around $89 with resistance at $90.
The outlook remains cautious amid persistent bond market pressure. While dividend income offers stability, the bearish technical trend and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflation concerns that could pressure bond prices further.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
